QNRX (48) MCRB (54) ACTU (43) QNTM (58) ⌘ Pro Terminal →

Karyopharm Therapeutics Inc. (KPTI) — RQD Stock Rating Cockpit

$0.88 +5.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Karyopharm Therapeutics Inc. (KPTI) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $20.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KPTI)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

4330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE5% OF RANGE

L: $0$0.88H: $11

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on KPTI

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

19/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like KPTI

✓Big institutional funds and options desks are actively positioning on the bullish side.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KPTI)

✓Walkthrough of KPTI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KPTI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -89.41%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.90H $0.90L $0.58C $0.88VOL 3.50M

RES: $12.28SUP: $-0.08SMA50: $1.22SMA200: $6.04

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KPTI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KPTI Butterfly Map → + Track KPTI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +0.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KPTI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KPTI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KPTI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KPTI)

Health Care Rank #423 of 1016 ⚔️ QNRX vs KPTI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KPTI vs. QNRX, MCRB, ACTU, QNTM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Karyopharm Therapeutics Inc. (KPTI) ranks #423 by composite RQD confidence (47/100, grade D) and #833 by equity capitalization ($20.0M). Within this direct 5-issuer industry benchmark cohort, KPTI leads on earnings valuation at N/A trailing P/E, while KPTI leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with KPTI at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KPTI ACTIVE Karyopharm Therapeutics Inc.	D	47/100	—	—	-35.0%	+5.73%	$20.0M	Benchmark Subject
QNRX Quoin Pharmaceuticals Ltd.	D	48/100	—	—	-35.0%	+0.97%	$19.9M	/qnrx-vs-kpti →
MCRB Seres Therapeutics Inc.	D+	54/100	—	—	-35.0%	+8.94%	$19.6M	/mcrb-vs-kpti →
ACTU Actuate Therapeutics Inc.	D-	43/100	—	—	-35.0%	-3.21%	$20.4M	/actu-vs-kpti →
QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares	D+	58/100	—	—	—	+2.95%	$20.7M	/qntm-vs-kpti →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001503802

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Karyopharm Therapeutics Inc. (KPTI) reported GAAP revenue of $146.1M (+0.6% vs. FY2024 revenue of $145.2M , and +0.0% cumulative change since FY2023) , GAAP net income of -$196.0M, operating cash flow of -$75.4M, and free cash flow of -$75.4M (+40.9% YoY). On the balance sheet, KPTI closed FY2025 with $108.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$146.1M	-$196.0M	-$75.4M	-$75.4M	$108.4M	—
FY2024 (FY)	2024-12-31	$145.2M	-$76.4M	-$127.5M	-$127.6M	$164.4M	—
FY2023 (FY)	2023-12-31	$146.0M	-$143.1M	-$92.7M	-$92.7M	—	—

3. KPTI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KPTI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.88 (+5.73% 1D, market cap $20.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KPTI ranks #423 in composite RQD confidence.

How does KPTI compare to QNRX and MCRB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KPTI carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, QNRX (Quoin Pharmaceuticals Ltd.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $19.9M) and MCRB (Seres Therapeutics Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -35.0%, cap $19.6M). Among the 5-stock peer group, KPTI leads on earnings multiple (N/A) while KPTI leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KPTI?

Per KPTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001503802), Karyopharm Therapeutics Inc. generated $146.1M in revenue (+0.6% YoY), -$196.0M in net income, and -$75.4M in free cash flow against $108.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KPTI trading relative to its 50-day, 200-day, and 52-week technical levels?

KPTI last traded at $0.88 (+5.73% on volume of 6,845,561 shares), positioning the stock -27.87% below its 50-day simple moving average ($1.22) and -85.43% below its 200-day simple moving average ($6.04). Across its 52-week range of $0.31 to $10.99, KPTI sits at the 5.3% percentile with a 14-day RSI of 43.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.99).

KPTI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell KPTI stock right now?

Karyopharm Therapeutics Inc. (KPTI) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is KPTI's 12-month price target and RQD AI Jury consensus?

KPTI's 12-month base price target is $0.84 (range $0.66 to $11.54), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: KPTI RQD Cockpit KPTI 12M Forecast KPTI Earnings & Move KPTI Dividends & DRIP KPTI Insiders & 13F KPTI Whale Options KPTI Profit Sankey KPTI News & Why